Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Romain Guyon along with three others received the 2022 Michelson Prizes in a virtual award ceremony in collaboration with Keystone Symposia on March 24, 2023. The Michelson Prizes are awarded by Michelson Medical Research Foundation and Human Immunome Project annually to support early-career investigators working to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. These distinguished scientists comprise the 5th class of Michelson Prize laureates, joining an international group of researchers charting the future of human health.


Romain was awarded the NDM Prize Studentship at Oxford where he is currently studying for a DPhil in Clinical Medicine, based between the Jenner Institute and the Institute of Biomedical Engineering (IBME), working on the development of single-dose vaccine technologies, and microparticle drug delivery.


“Demonstration of new single-dose vaccine technology towards a first-in-man clinical application.”

Single-dose immunization could provide an effective solution to improving global vaccination coverage and easing the logistical and cost burdens during outbreaks.  Guyon uses a novel microfluidics system to generate biodegradable particles encapsulating the vaccine booster dose to be delivered with the priming vaccine dose in a single injection, delaying the booster release in the body. His successful proposal will assess the utility of this technology using the licensed rabies vaccine for single-visit post-exposure prophylaxis and assess scale-up feasibility to facilitate a first-in-human clinical trial.